Latest H5N1 clinical trials Stories
BEIJING, Sept. 5, 2014 /PRNewswire/ -- Sinovac Biotech Ltd.
Unprecedented international consortium -- including the University of Maryland School of Medicine and NIH -- now assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine
As if West Nile virus and malaria weren't enough, mosquitoes are now delivering the chikungunya virus. As of 2013, it has reached the Western Hemisphere and there are no vaccines or specific drug treatments to deal with it.
High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications.
- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older - LYON, France,
- Largest U.S.
- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today
VIENNA, June 12, 2014 /PRNewswire/ -- A prophylactic vaccine candidate against Chikungunya fever, developed by the Austrian biotech company Themis Bioscience GmbH induces
New research, by a team from Rhode Island Hospital (RIH), has uncovered a protein, or antigen, that is essential for malaria-causing parasites to escape from red blood cells. This protein also generates antibodies that can hinder the ability of malaria parasites to multiply, which may protect against severe malaria infection.
Results indicate vaccine generates an immune response against key toxins in volunteers and establish dosing for Phase III BOSTON, May 19, 2014 /PRNewswire/ -- Sanofi Pasteur, the vaccines
- The parings of haberdine; also, any kind of fragments.